EA201291168A1 - Фармацевтические композиции и способы их получения - Google Patents

Фармацевтические композиции и способы их получения

Info

Publication number
EA201291168A1
EA201291168A1 EA201291168A EA201291168A EA201291168A1 EA 201291168 A1 EA201291168 A1 EA 201291168A1 EA 201291168 A EA201291168 A EA 201291168A EA 201291168 A EA201291168 A EA 201291168A EA 201291168 A1 EA201291168 A1 EA 201291168A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
pharmaceutical compositions
production
pazopanib
contain
Prior art date
Application number
EA201291168A
Other languages
English (en)
Inventor
Маниш К. Гупта
Original Assignee
Глэксо Уэлкам Мэньюфэкчуринг Пте Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глэксо Уэлкам Мэньюфэкчуринг Пте Лтд. filed Critical Глэксо Уэлкам Мэньюфэкчуринг Пте Лтд.
Publication of EA201291168A1 publication Critical patent/EA201291168A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Описаны фармацевтические композиции, которые содержат приблизительно 10 мг пазопаниба/мл композиции и от приблизительно 2 до приблизительно 13% мас./мас. модифицированного циклодекстрина, а также способы их получения.
EA201291168A 2010-05-05 2011-05-05 Фармацевтические композиции и способы их получения EA201291168A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33171510P 2010-05-05 2010-05-05
PCT/US2011/035363 WO2011140343A1 (en) 2010-05-05 2011-05-05 Pharmaceutical compositions and methods of making same

Publications (1)

Publication Number Publication Date
EA201291168A1 true EA201291168A1 (ru) 2013-06-28

Family

ID=44851507

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201291168A EA201291168A1 (ru) 2010-05-05 2011-05-05 Фармацевтические композиции и способы их получения

Country Status (26)

Country Link
US (3) US20120028918A1 (ru)
EP (1) EP2566331B1 (ru)
JP (1) JP5835717B2 (ru)
KR (1) KR20130071434A (ru)
CN (1) CN102970871A (ru)
AR (1) AR081364A1 (ru)
AU (1) AU2011247995B2 (ru)
BR (1) BR112012028291A2 (ru)
CA (1) CA2798386A1 (ru)
CL (1) CL2012003075A1 (ru)
CO (1) CO6640262A2 (ru)
CR (1) CR20120556A (ru)
DO (1) DOP2012000281A (ru)
EA (1) EA201291168A1 (ru)
ES (1) ES2519615T3 (ru)
HK (1) HK1175947A1 (ru)
IL (1) IL222751A0 (ru)
MA (1) MA34286B1 (ru)
MX (1) MX2012012837A (ru)
NZ (1) NZ603411A (ru)
PE (1) PE20130217A1 (ru)
SG (1) SG185087A1 (ru)
TW (1) TW201206908A (ru)
UY (1) UY33367A (ru)
WO (1) WO2011140343A1 (ru)
ZA (1) ZA201208265B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
AR081364A1 (es) * 2010-05-05 2012-08-29 Glaxo Wellcome Mfg Pte Ltd Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
EP2640360A2 (en) 2010-11-19 2013-09-25 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP3903733A1 (en) 2011-09-16 2021-11-03 ForSight Vision4, Inc. Fluid exchange apparatus
MX2014009892A (es) * 2012-02-17 2015-02-12 Pharmacyclics Inc Combinaciones de inhibidor de histona desacetilasa y pazopanib y usos de las mismas.
CN104160762B (zh) * 2012-03-08 2019-03-15 三星电子株式会社 用于控制无线通信系统中的服务的方法
EP2968113B8 (en) * 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
DK3039424T3 (da) 2013-08-28 2020-08-31 Crown Bioscience Inc Taicang Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse
US9474756B2 (en) * 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
CN114587774A (zh) 2014-11-10 2022-06-07 弗赛特影像4股份有限公司 治疗眼睛的系统
US11129900B2 (en) 2014-12-25 2021-09-28 Kyoto University Cytophilic peptide-fused high-density lipoprotein, and delivery of drug to posterior segment of eye by ocular installation of said fusion
AR108177A1 (es) 2016-04-05 2018-07-25 Forsight Vision4 Inc Dispositivos de suministro de fármacos oculares implantables
CN110769853B (zh) * 2017-04-17 2022-06-03 北京生命科学研究所 治疗雄性衰老
TWI770246B (zh) * 2017-08-02 2022-07-11 昊運股份有限公司 新穎化合物及包含其之醫藥組成物
WO2019234632A1 (en) * 2018-06-07 2019-12-12 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
CN113350351A (zh) * 2020-03-13 2021-09-07 青晓制药公司 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用
US20240050429A1 (en) * 2022-08-10 2024-02-15 Qx Therapeutics, Inc. Pazopanib pharmaceutical composition, injection and preparation method and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20080293691A1 (en) * 2005-11-29 2008-11-27 Smithkline Beecham Corporation Treatment Method
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
JP2009534409A (ja) * 2006-04-18 2009-09-24 イーケーアール セラピューティクス， インク． 予備混合即時使用静脈内ボーラス組成物および使用方法
ES2830024T3 (es) * 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
EP2252616B1 (en) * 2008-01-30 2014-07-23 Genentech, Inc. Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
CN102573477A (zh) * 2009-07-16 2012-07-11 葛兰素惠尔康制造业私人有限公司 治疗方法
WO2011039648A1 (en) * 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Methods of administration and treatment
TW201201808A (en) * 2010-01-06 2012-01-16 Glaxo Wellcome Mfg Pte Ltd Treatment method
AR081364A1 (es) * 2010-05-05 2012-08-29 Glaxo Wellcome Mfg Pte Ltd Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
US20130023550A1 (en) * 2010-05-05 2013-01-24 Glaxo Wellcome Manufacturing Pte, Ltd Pharmaceutical compositions and methods of making same

Also Published As

Publication number Publication date
AR081364A1 (es) 2012-08-29
CO6640262A2 (es) 2013-03-22
CR20120556A (es) 2013-02-20
ES2519615T3 (es) 2014-11-07
DOP2012000281A (es) 2013-05-31
US20120028918A1 (en) 2012-02-02
MA34286B1 (fr) 2013-06-01
WO2011140343A1 (en) 2011-11-10
EP2566331A1 (en) 2013-03-13
CN102970871A (zh) 2013-03-13
ZA201208265B (en) 2013-07-31
JP5835717B2 (ja) 2015-12-24
HK1175947A1 (en) 2013-07-19
UY33367A (es) 2011-10-31
US20150231265A1 (en) 2015-08-20
BR112012028291A2 (pt) 2015-09-15
JP2013525501A (ja) 2013-06-20
KR20130071434A (ko) 2013-06-28
PE20130217A1 (es) 2013-03-21
AU2011247995A1 (en) 2012-12-13
NZ603411A (en) 2014-10-31
SG185087A1 (en) 2012-12-28
IL222751A0 (en) 2012-12-31
CA2798386A1 (en) 2011-11-10
EP2566331B1 (en) 2014-09-03
US20110281901A1 (en) 2011-11-17
CL2012003075A1 (es) 2013-03-08
TW201206908A (en) 2012-02-16
EP2566331A4 (en) 2013-09-18
MX2012012837A (es) 2013-01-24
AU2011247995B2 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
EA201291168A1 (ru) Фармацевтические композиции и способы их получения
CY1123549T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
CY1119245T1 (el) Φαρμακευτικη συνθεση καρβετοκινης
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
EA201200794A1 (ru) Триазолопиридины
EA201171151A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
IN2014CN04961A (ru)
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201190297A1 (ru) Инъецируемые композиции мелфалана, содержащие производное циклодекстрина, и способы их получения и применения
EA201590879A1 (ru) Арилконденсированные и гетероарилконденсированные лактамы
EA201301181A1 (ru) Триазолопиридины
EA200971140A1 (ru) Триарильные соединения и композиции, их содержащие
EA201890333A1 (ru) Противовирусные соединения
EA201270520A1 (ru) Новые соединения, эффективные в качестве ингибиторов ксантиноксидазы, способ их получения и содержащая их фармацевтическая композиция
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
CO6511271A2 (es) Compuestos de imidazopiridinil-aminopiridina sustituida
EA200702329A1 (ru) Замещенные пирролпиридины, содержащие их композиции, способ получения и применение
EA201390381A1 (ru) Триазиноксадиазолы
EA201290884A1 (ru) Устойчивые к спирту кишечнорастворимые фармацевтические композиции
EA201171435A1 (ru) Твердые фармацевтические композиции и способы их получения
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
NI201400022A (es) Composición farmacéutica que comprende un ciclopolisacárido
EA201690520A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов